The Use of Allogenic Platelet Rich Plasma for the Treatment of Diabetic Foot Ulcer

Sponsor

Hanan Jafar (Other)

Overall Status

Unknown status

CT.gov ID

NCT02972528

Collaborator

(none)

Enrollment

Location

Arms

30.9

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Allogenic defibrinated platelet rich plasma lysate will be injected in patients diagnosed with Diabetic Foot Ulcer (DFU).

Condition or Disease	Intervention/Treatment	Phase
Diabetic Foot Ulcer	Biological: Platelet Lysate Biological: Platelet Poor Plasma	Phase 1/Phase 2

Detailed Description

In this study, allogenic, defibrinated platelet rich plasma lysate will be used as a direct injection into the periphery of diabetic chronic foot ulcers which have not healed using standard of care. Investigators anticipate a significant response in treated individuals measured by the percentage of skin restoration achieved.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

30 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Care Provider)

Primary Purpose:

Treatment

Official Title:

Allogeneic Defibrinated Platelet Rich Plasma Lysate for the Healing of Chronic Diabetic Foot Ulcer

Actual Study Start Date :

Feb 3, 2018

Anticipated Primary Completion Date :

Feb 1, 2020

Anticipated Study Completion Date :

Sep 1, 2020

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Platelet Lysate Patients will receive 5ml peri-lesional injections of Platelet Lysate at weekly intervals, for 4 consecutive times (week 0,1,2,3).	Biological: Platelet Lysate Direct injection of allogenic Platelet Lysate
Placebo Comparator: Platelet Poor Plasma Patients will receive 5ml peri-lesional injections of Platelet Poor Plasma at weekly intervals, for 4 consecutive times (week 0,1,2,3).	Biological: Platelet Poor Plasma Direct injection of allogenic Platelet Poor Plasma

Arm

Intervention/Treatment

Active Comparator: Platelet Lysate

Patients will receive 5ml peri-lesional injections of Platelet Lysate at weekly intervals, for 4 consecutive times (week 0,1,2,3).

Biological: Platelet Lysate

Direct injection of allogenic Platelet Lysate

Placebo Comparator: Platelet Poor Plasma

Patients will receive 5ml peri-lesional injections of Platelet Poor Plasma at weekly intervals, for 4 consecutive times (week 0,1,2,3).

Biological: Platelet Poor Plasma

Direct injection of allogenic Platelet Poor Plasma

Outcome Measures

Primary Outcome Measures

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection [3 months]
Evaluate the safety of this treatment, by gathering and assessing the number, timing, severity, duration, and resolution of related adverse events.

Secondary Outcome Measures

Assess the efficacy of allogenic Platelet Lysate injection by clinical examination [4 months]
To determine short term speed and effectiveness of allogeneic, platelet rich plasma lysate on the healing of diabetic foot ulceration compared with Platelet Poor Plasma by measuring the diameter of ulcers.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Persons with type 1 or type 2 diabetes between the ages of 18 and 70 with an ulcer of at least 4 weeks duration
HemoglobinA1C (HbA1c) < 12
Index foot ulcer located on the plantar, medial, or lateral aspect of the foot (including all toe surfaces); and wound area (length x width) measurement between 2 cm2 and 20 cm2, inclusive.
Wounds located under a Charcot deformity had to be free of acute changes and must have under gone appropriate structural consolidation.
The index ulcer had to be clinically non-infected and full - thickness without exposure of bone, ligaments, or tendons.
The protocol requires that post debridement the ulcer would be free of necrotic debris, foreign bodies or sinus tracts.
Non- invasive vascular testing ankle brachial index (ABI).
Physical examination (including a Semmes-Weinstein monofilament test for neuropathy)
Blood tests to be obtained Complete Blood Count and HbA1c.
Approved, informed, signed consent.
Negative test for Hepatitis C (HC), Hepatitis B (HB), Human Immunodeficiency Virus 1 and 2 (HIVI and II), Venereal Disease Research Laboratory (VDRL).

Exclusion Criteria:

Patient currently enrolled in another investigational device or drug trial or previously enrolled (within last 30 days) in investigative research of a device or pharmaceutical agent.
Ulcer decreased ≥50% in area during 7-day screening period.
Ulcer is due to non-diabetic etiology.
Patient's blood vessels are non-compressible for ABI testing.
Evidence of gangrene in ulcer or on any part of the foot.
Patient has radiographic evidence consistent with diagnosis of acute Charcot foot.
Patient is currently receiving or has received radiation or chemotherapy within 3 months of randomization.
Patient has received growth factor therapy within 7 days of randomization.
Screening hemoglobin <10.5 mg/dL.
Screening platelet count < 100 x 109/L.
Patient is undergoing renal dialysis, has known immune insufficiency, known abnormal platelet activation disorders - ie, gray platelet syndrome, liver disease, active cancer (except remote basal cell of the skin), eating/ nutritional,hematologic, collagen vascular disease, rheumatic disease, or bleeding disorders.
History of peripheral vascular repair within the 30 days of randomization
Patient has known or suspected osteomyelitis.
Surgical correction (other than debridement) required for ulcer to heal.
Index ulcer has exposed tendons, ligaments, muscle, or bone.
Patient is known to have a psychological, developmental, physical, emotional, or social disorder, or any other situation that may interfere with compliance with study requirements and/or healing of the ulcer
History of alcohol or drug abuse within the last year prior to randomization.
Patient has inadequate venous access for blood draw.
Positive test for HC, HB, HIVI and II, VDRL.